Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Schroll, M. Arzt, D. Sebah, B. Stoelcker, A. Luchner, F. C. Blumberg, M. Pfeifer (Regensburg, Donaustauf, Recklinghausen, Germany). Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension. Eur Respir J 2007; 30: Suppl. 51, 490

Member's Comments

No comment yet.

Related content which might interest you: Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001 Dual-targeting of peripheral cannabinoid-1 receptors and inducible NO synthase in pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Effects of endothelial nitric oxide synthase enzyme, angiotensin converting enzyme and serotonin transporter genotypes on pulmonary hypertension in COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Polymorphism of prostacyclin synthase gene in pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 5s Year: 2002 Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Combination of inhaled nitric oxide and an endothelinA-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 271s Year: 2003 Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007